Waldenström’s Macroglobulinemia
by Véronique Leblond /
2016 / English / PDF
5.2 MB Download
This book sheds new light on clinical, biological and therapeutic
data on the rare disease Waldenström’s Macroglobulinemia (WM)
with the participation of widely-recognized experts, involved in
this field. It represents the efforts of physicians, scientists
and patients, all around the world, to better understand and cure
this rare disease.
This book sheds new light on clinical, biological and therapeutic
data on the rare disease Waldenström’s Macroglobulinemia (WM)
with the participation of widely-recognized experts, involved in
this field. It represents the efforts of physicians, scientists
and patients, all around the world, to better understand and cure
this rare disease.
Considerable advances in the diagnosis, treatment indications,
response criteria, prognostic factors and treatment options have
been made since Dr Jan Waldenström first reported this “new
syndrome“ 70 years ago. Particularly instrumental in advancing of
our understanding of WM have been the eight international
workshops devoted to this disease. New, exciting molecular data
have recently been reported, allowing us to revisit the oncogenic
events leading to WM B-cell proliferation and to use newly
available compounds targeting oncogenic pathways.
Considerable advances in the diagnosis, treatment indications,
response criteria, prognostic factors and treatment options have
been made since Dr Jan Waldenström first reported this “new
syndrome“ 70 years ago. Particularly instrumental in advancing of
our understanding of WM have been the eight international
workshops devoted to this disease. New, exciting molecular data
have recently been reported, allowing us to revisit the oncogenic
events leading to WM B-cell proliferation and to use newly
available compounds targeting oncogenic pathways.